Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implicationsFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 13 April 2017

References

• UNAIDS. Report on the Global AIDS Epidemics. Ps 16-29. <http://www.unaids.org/documents/20101123_globalreport_em.pdf>; 2010.
   Google Scholar
• UNAIDS. Namibia Report on AIDS Epidemics update. <http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_epidermiologydata>; 2013.
   Google Scholar
• Republic of Namibia, Ministry of Health and Social Services. Directorate of special programmes Surveillance report of the 2014 national HIV sentinel survey. <http://www.mhss.gov.na/files/downloads/12f_2014%20National%20HIV%20Sentinel%20Survey.pdf>; 2014.
   Google Scholar
• Global HIV/AIDS response progress report 2014. UNICEF, UNAIDS. <http://www.unaids.org/sites/default/files/media_asset/GARPR_2014_guidelines_en_0.pdf>.
   Google Scholar
• Mwamakimbula NWR, Prevalence and severity of adverse drug reactions among adult patients using default first line and modified antiretroviral combinations in Mbeya region, Tanzania. <http://ihi.eprints.org/1627/1/William_Ndimbumi_Mwamakimbula_Reuben.pdf>; 2012.
   Google Scholar
• U.SpenglerM.LichterfeldJ.K.RockstrohAntiretroviral drug toxicity – a challenge for the hepatologist?J Hepatol3622002283294
   Web of Science ®Google Scholar
• G.TeklayB.LegesseM.LegesseAdverse effects and regimen switch among patients on antiretroviral treatment in a resource limited setting in EthiopiaJ Pharmacovigilance120134
   Google Scholar
• I.CassettiJ.V.MadrugaJ.M.SuleimanThe safety and efficacy of Tenofovir DF in combination with lamivudine and Efavirenz through 6 years in antiretroviral-naive HIV-1-infected patientsHIV Clin Trials82007164172
   PubMed Web of Science ®Google Scholar
• B.H.ChiA.MwangoM.GigantiEarly clinical and programmatic outcomes with Tenofovir-based antiretroviral therapy in ZambiaJ Acquired Immune Deficiency Syndrome5420106370
   Web of Science ®Google Scholar
• B.WoldemedhinN.T.WabeThe reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in southern EthiopiaN Am J Med Sci420121923
   Google Scholar
• K.F.H.LucienA.N.J.ClementN.P.FonP.WeledjiC.P.NdikvuThe effects of antiretroviral treatment on liver function enzymes among HIV-Infected out-patients attending the central hospital of Yaounde, CameroonAfr J Clin Exp Microbiol113201015951689
   Google Scholar
• Z.ShubberAdverse events associated with Nevirapine and Efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysisAIDS27201314031412
   PubMed Web of Science ®Google Scholar
• N.KontorinosD.DieterichHepatotoxicity of antiretroviral therapyAIDS Rev5120033643
   Google Scholar
• F.MaggioloC.AriciM.AiroldiReasons for discontinuation of Nevirapine containing HAARTJ Antimicrob Chemother592007569572
   PubMed Web of Science ®Google Scholar
• F.KalemeeraC.MbangoM.MubitaE.NaikakuR.GaidaB.GodmanEffect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in NamibiaExp Rev Anti-infective Ther1482016777783
   PubMed Web of Science ®Google Scholar
• S.WakibiZ.Ng'ang'aG.MbuguaFactors associated with non-adherence to highly active antiretroviral therapy in Nairobi, KenyaAIDS Res Ther58201143
   Web of Science ®Google Scholar
• P.BossiD.ColinF.BricaireE.CaumesHypersensitivity syndrome associated with efavirenz therapyClin Infectious Diseases302000227228
   PubMed Web of Science ®Google Scholar
• E.MartinezJ.L.BlancoA.ArnaizHepatotoxicity in HIV-1–infected patients receiving Nevirapine-containing antiretroviral therapyAcquired Immune Deficiency Syndrome15200112611268
   Google Scholar
• I.OfotokunS.E.SmithsonC.LuK.A.EasleyJ.L.LennoxLiver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapyAm J Med Sci33452007334341
   Web of Science ®Google Scholar
• I.SabolicA.R.AsifW.E.BudachC.WankeA.BahnG.BurckhardtGender differences in kidney functionPflugers Archiv45532007397429
   Web of Science ®Google Scholar
• Barlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses & Opportunistic Infections. Chicago, IL. 2001; Abstract 19.
   Google Scholar
• M.M.De MaatR.ter HeineE.C.Van GorpCase series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatmentAIDS1715200322092214
   Web of Science ®Google Scholar
• R.PalmonB.C.KooD.A.ShoulzLack of hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitorsJ Acquired Immune Deficiency Syndrome292002340345
   PubMed Web of Science ®Google Scholar
• M.S.SulkowskyD.L.ThomasS.H.MehtaHepatotoxicity associated with nevirapine- or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infectionsJ Hepatol352002182189
   Web of Science ®Google Scholar
• G.VerucchiIncidence of liver toxicity in HIV infected patients receiving isolated dual nucleoside analogue antiretroviral therapyJ Acquired Immune Deficiency Syndrome332003546548
   PubMed Web of Science ®Google Scholar
• R.GaidaI.TruterC.GroblerT.KotzeB.GodmanA review of trials investigating efavirenz-induced neuropsychiatric side effects and the implicationsExp Rev Anti-infective Ther1442016377388
   PubMed Web of Science ®Google Scholar
• Republic of Namibia, Ministry of Health and Social Services Directorate of Special Programmes. National Guidelines for Antiretroviral Therapy First Edition; 2003.
   Google Scholar
• Republic of Namibia, Ministry of Health and Social Services Directorate of Special Programmes. National Guidelines for Antiretroviral Therapy second Edition; 2010.
   Google Scholar
• Republic of Namibia, Ministry of Health and Social Services Directorate of Special Programmes. National Guidelines for Antiretroviral Therapy Fourth Edition; 2014.
   Google Scholar
• Ministry of health and Social Services (MoHSS), National Tuberculosis and leprosy Control Program 2009/2010 Annual Report, Windhoek MoSS.
   Google Scholar
• World Health Organization. Global Status Report on Alcohol. <http://www.who.int/substance_abuse/publications/global_status_report_2004_overview.pdf>; 2004.
   Google Scholar
• Veira DEO, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol 2008; 34. <http://www.scielo.br/pdf/jbpneu/v34n12/en_v34n12a10.pdf>.
   Google Scholar
• M.JavariG.ShalviriGholamiJ.SalamzadehG.MaghooliMirsaeediAdverse reactions of anti-tuberculosis drugs in hospitalized patientsPDS1610200711041110
   Google Scholar
• WHO Toxicity Grading Scale for Determining. The Severity of Adverse Events. <http://www.icssc.org/Documents/Resources/AEManual2003Appendices>; 2003.
   Google Scholar
• C.Uberti-FoppaA.De BonaL.GaliLiver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levelsJ Acquired Immune Deficiency Syndrome4120066367
   PubMed Web of Science ®Google Scholar
• Carter M. ALT levels may not give true picture of liver disease in HIV/HCV co-infected, suggests study. <http://www.aidsmap.com/ALT-levels-may-not-give-true-picture-of-liver-disease-in-HIVHCV-coinfected-suggests-study/page/1422831/>; 2006.
   Google Scholar
• S.BoseA.VaranasiG.MoDemographic, socio-economic and psychological determinants of HIV treatment: a community out-patient experienceBJMP2220094245
   Google Scholar
• M.J.NunezMartin-CarboneroV.MorenoE.ValenciaJ.Garcia-SamaniegoJ.Gonzalez-CastilloImpact of antiretroviralAIDS222006825829
   Google Scholar
• J.H.LewisThe rational use of potentially hepatotoxic medications in patients with underlying liver diseaseInforma Healthcare12002159172
   Google Scholar
• Aronson JK, Torpey K, Lartey M. Side effects of drugs annual 2011; 33: 577–88. <http://https://www.elsevier.com/books/book-series/side-effects-of-drugs-annual_>.
   Google Scholar
• A.BonjochHigh rate of reversibility of renal damage in a cohort of HIV-infected patients receiving Tenofovir-containing antiretroviral therapyAntiviral Res9620126569
   PubMed Web of Science ®Google Scholar
• R.D.MooreAnaemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapySemin Hematol720001823
   Web of Science ®Google Scholar
• C.NjugunaC.OrrellR.KaplanL.G.BekkerR.WoodS.D.LawnRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirPLOS One852013e63596
   Web of Science ®Google Scholar
• Bimenya GS. International system of units in clinical sciences: reference values for analytes in clinical chemistry, vol. 44, 1st ed., Kampala; 2000.
   Google Scholar
• G.N.LoanouE.J.BoykoS.P.LeeThe prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002Am J Gastroenterol10120067682
   Web of Science ®Google Scholar
• J.M.TetraultJ.P.TateK.A.McGinnisVeterans Aging Cohort Study Team. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexoneAlcohol Clin Exp Res3622012318324
   Web of Science ®Google Scholar
• R.ManfrediL.CalzaRecent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patientsAIDS Patient Care STDs222008279290
   Web of Science ®Google Scholar
• C.HawkinsC.AchenbachW.FrydaD.NgareR.MurphyAntiretroviral durability and tolerability in HIV-infected adults living in urban KenyaJAIDS4532007304310
   Google Scholar